September 22
Denteric Pty Ltd – Vaccine for P. gingivalis-associated dementia
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Robinson Research Institute is a collective of internationally renowned researchers in human reproduction, pregnancy and child health at the University of Adelaide.
ViewThe Malaghan Institute of Medical Research is New Zealand’s leading independent biomedical research institute, with a history spanning over five decades. The Institute’s research centers on the immune system, and how it may be harnessed to treat human disease. Pioneering research programmes explore fields of immunotherapy such as cancer, asthma and allergy, infectious diseases, gut health and brain health.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn more